Skye Bioscience, Inc. (SKYE)

NGM – Цена в реальном времени. Валюта: USD

0.81

-0.07 (-7.56%)

При закрытии: May 12, 2026, 4:00 PM EDT

0.80

-0.01 (-1.52%)

До открытия: May 13, 2026, 8:18 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Skye Bioscience, Inc. (SKYE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Skye Bioscience, Inc. (SKYE)

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Search stocks

Skye Bioscience, Inc. (SKYE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Skye Bioscience, Inc. (SKYE)

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Видео

No Data

Пресс-релизы

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit